Your views needed for a NICE appraisal

Printer-friendly version
Entrance of NICE London office

The National Institute for Health and Care Excellence (NICE) will be appraising a treatment called risankizumab for treating moderate to severe plaque psoriasis in May 2019.

The treatment is classed as a systemic biologic agent, given as a self-administered subcutaneous injection.

The proposed use of the treatment will probably be at the same point in the psoriasis treatment pathway as other similar treatments which include: adalimumab, etanercept, ustekinumab, ixekizumab, brodalumab, guslekumab and infiximab.

To learn more and to give your views go to the survey